戻る Agenda
ON DEMAND - Bridging Bench to Bedside With Novel Biomarkers
Session Chair(s)
Anita Nelsen
Executive Vice President, Translational Medicine
Parexel, United States
Precision medicines, those which leverage biomarker(s) to determine who is most likely to benefit, are changing drug development. Biomarkers are expanding our understanding of disease, improving ability to identify and develop novel drug targets, understanding variation in drug response, positively impacting likelihood of drug approval and reimbursement and ultimately improving patient outcomes. Yet finding robust and clinically useful biomarkers can be like finding a needle in a haystack. Through case studies, this session will explore the value of biomarkers across drug discovery and development. It will also address the challenges of identifying and translating biomarkers to benefit patients. We will explore approaches, including through use of AI, meta-analysis of clinical trial data and real world data to increase the odds of finding robust and relevant biomarkers in increasing vast and complicated data sets.
Learning Objective : Describe methods for biomarker discovery using artificial intelligence (AI) and large and complex data sets; Discuss how biomarkers are evaluated in clinical development; Identify best practices for biomarker data handling for use and reuse.
Speaker(s)
Using AI-Driven Biomarkers for Advancing Drug Development
Richard Gliklich, MD
OM1, United States
Founder
The Future is Here: Omics Biomarker Discovery and Strategies for Use in Clinical Trials
Misha Kapushesky, PHD
Genestack Ltd, United Kingdom
Chief Executive Officer